Histone deacetylases and the immunological network: implications in cancer and inflammation

[1]  B. Conley,et al.  Histone Deacetylation , 2020, Drugs in R&D.

[2]  W. Yeo,et al.  The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines , 2010, Investigational New Drugs.

[3]  P. Atadja.  Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. , 2009, Cancer letters.

[4]  Jessica E. Bolden,et al.  Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. , 2009, Cancer letters.

[5]  C. Deng,et al.  Recent progress in the biology and physiology of sirtuins , 2009, Nature.

[6]  Kazuhiro Ito,et al.  Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. , 2009, Biochemical and biophysical research communications.

[7]  M. Hummel,et al.  Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines. , 2009, Leukemia research.

[8]  Y. Gong,et al.  Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer. , 2009, Oncology reports.

[9]  I. Christensen,et al.  Histone deacetylase 1, 2, 6 and acetylated histone H4 in B‐ and T‐cell lymphomas , 2009, Histopathology.

[10]  P. Gimsing.  Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor , 2009, Expert opinion on investigational drugs.

[11]  M. F. Shannon,et al.  The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells. , 2009, International immunology.

[12]  T. Aune,et al.  Epigenetics and T helper 1 differentiation , 2009, Immunology.

[13]  A. Nanbo,et al.  HDAC3 influences phosphorylation of STAT3 at serine 727 by interacting with PP2A. , 2009, Biochemical and biophysical research communications.

[14]  T. Tomasi,et al.  miRNA regulation of cytokine genes. , 2009, Cytokine.

[15]  Wei-Guo Zhu,et al.  The changing face of HDAC inhibitor depsipeptide. , 2009, Current cancer drug targets.

[16]  R. Stauber,et al.  A phosphorylation-acetylation switch regulates STAT1 signaling. , 2009, Genes & development.

[17]  Z. Tian,et al.  Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis , 2009, Cancer Immunology, Immunotherapy.

[18]  G. Natoli.  When Sirtuins and NF-κB Collide , 2009, Cell.

[19]  Barbara Hero,et al.  Histone Deacetylase 8 in Neuroblastoma Tumorigenesis , 2009, Clinical Cancer Research.

[20]  W. Weichert,et al.  Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer , 2008, BMC Cancer.

[21]  T. Aune,et al.  T-Bet Dependent Removal of Sin3A-Histone Deacetylase Complexes at the Ifng Locus Drives Th1 Differentiation1 , 2008, The Journal of Immunology.

[22]  T. Suuronen,et al.  SIRT1 longevity factor suppresses NF‐κB ‐driven immune responses: regulation of aging via NF‐κB acetylation? , 2008, BioEssays : news and reviews in molecular, cellular and developmental biology.

[23]  L. Thompson,et al.  Therapeutic application of histone deacetylase inhibitors for central nervous system disorders , 2008, Nature Reviews Drug Discovery.

[24]  K. Aldape,et al.  Selective repression of YKL‐40 by NF‐κB in glioma cell lines involves recruitment of histone deacetylase‐1 and ‐2 , 2008, FEBS letters.

[25]  H. Koeffler,et al.  Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells , 2008, Leukemia.

[26]  W. Weichert,et al.  Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. , 2008, Neoplasia.

[27]  T. Lee,et al.  Control of cytokine gene transcription in Th1 and Th2 cells , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[28]  I. Christensen,et al.  A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia , 2008, European journal of haematology.

[29]  C. Scrideli,et al.  Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas , 2008, BMC Cancer.

[30]  Lili Wang,et al.  Rapid histone deacetylation and transient HDAC association in the IL-2 promoter region of TSST-1-stimulated T cells. , 2008, Immunology letters.

[31]  N. Suttorp,et al.  Histone Acetylation and Flagellin Are Essential for Legionella pneumophila-Induced Cytokine Expression1 , 2008, The Journal of Immunology.

[32]  Gordon K Smyth,et al.  Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma , 2008, Clinical Cancer Research.

[33]  F. Dequiedt,et al.  Caspase-8 Cleaves Histone Deacetylase 7 and Abolishes Its Transcription Repressor Function* , 2008, Journal of Biological Chemistry.

[34]  L. Siu,et al.  Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor , 2008, Expert opinion on investigational drugs.

[35]  F. Sánchez‐Madrid,et al.  HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. , 2008, Trends in cell biology.

[36]  M. Carducci,et al.  Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay , 2008, Clinical Cancer Research.

[37]  D. Lombardo,et al.  High Histone Deacetylase 7 (HDAC7) Expression Is Significantly Associated with Adenocarcinomas of the Pancreas , 2008, Annals of Surgical Oncology.

[38]  A. Dueñas-González,et al.  Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. , 2008, Cancer treatment reviews.

[39]  B. Seliger.  Molecular mechanisms of MHC class I abnormalities and APM components in human tumors , 2008, Cancer Immunology, Immunotherapy.

[40]  Richard A Flavell,et al.  Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. , 2008, Immunity.

[41]  A. Kalita,et al.  MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo , 2008, Molecular Cancer Therapeutics.

[42]  R. Johnstone,et al.  Histone deacetylase inhibitors in lymphoma and solid malignancies , 2008, Expert review of anticancer therapy.

[43]  E. Seto,et al.  The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men , 2008, Nature Reviews Molecular Cell Biology.

[44]  I. Adcock,et al.  The role of histone deacetylases in asthma and allergic diseases. , 2008, The Journal of allergy and clinical immunology.

[45]  W. Weichert,et al.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy , 2008, British Journal of Cancer.

[46]  H. Hayashi,et al.  The interaction with Sp1 and reduction in the activity of histone deacetylase 1 are critical for the constitutive gene expression of IL‐1α in human melanoma cells , 2008, Journal of leukocyte biology.

[47]  Z. Xiao,et al.  Pro-IL-16 Recruits Histone Deacetylase 3 to the Skp2 Core Promoter through Interaction with Transcription Factor GABP1 , 2008, The Journal of Immunology.

[48]  M. Mapara,et al.  The histone deacetylase inhibitor, PXD101, potentiates bortezomib‐induced anti‐multiple myeloma effect by induction of oxidative stress and DNA damage , 2007, British journal of haematology.

[49]  R. Johnstone,et al.  Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents , 2007, Expert review of anticancer therapy.

[50]  P. Marks,et al.  Histone Deacetylase Inhibitors: Overview and Perspectives , 2007, Molecular Cancer Research.

[51]  T. Robak,et al.  Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity. , 2007, Mini reviews in medicinal chemistry.

[52]  N. Gattermann,et al.  Valproic acid for the treatment of myeloid malignancies , 2007, Cancer.

[53]  W. Hancock,et al.  Regulating regulatory T cells to achieve transplant tolerance. , 2007, Hepatobiliary & pancreatic diseases international : HBPD INT.

[54]  O. Politz,et al.  MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. , 2007, The international journal of biochemistry & cell biology.

[55]  K. He,et al.  Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma , 2007, Clinical Cancer Research.

[56]  F. Garrido,et al.  Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. , 2007, Tissue antigens.

[57]  T. Mahmoudi,et al.  Myosin phosphatase dephosphorylates HDAC7, controls its nucleocytoplasmic shuttling, and inhibits apoptosis in thymocytes. , 2007, Genes & development.

[58]  Yuan Shen,et al.  FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression , 2007, Proceedings of the National Academy of Sciences.

[59]  B. Rigas.  The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia , 2007, Current opinion in gastroenterology.

[60]  M. V. Van Dyke,et al.  Depletion of Histone Deacetylase I Protein: A Common Consequence of Inflammatory Cytokine Signaling? , 2006, Cell cycle.

[61]  R. Kannagi,et al.  Interaction of GATA-3/T-bet transcription factors regulates expression of sialyl Lewis X homing receptors on Th1/Th2 lymphocytes , 2006, Proceedings of the National Academy of Sciences.

[62]  Hui Li,et al.  HPV16E7 mediates HADC chromatin repression and downregulation of MHC class I genes in HPV16 tumorigenic cells through interaction with an MHC class I promoter. , 2006, Biochemical and biophysical research communications.

[63]  S. Fortuni,et al.  Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors , 2006, Nature Medicine.

[64]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[65]  K. Bhalla,et al.  A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies , 2006, Clinical Cancer Research.

[66]  Xia Zhang,et al.  Dynamic and Transient Remodeling of the Macrophage IL-10 Promoter during Transcription1 , 2006, The Journal of Immunology.

[67]  Satoshi Inoue,et al.  Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. , 2006, Cancer research.

[68]  Y. Hayashizaki,et al.  LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  A. Karpf.  A Potential Role for Epigenetic Modulatory Drugs in the Enhancement of Cancer/Germ-Line Antigen Vaccine Efficacy , 2006, Epigenetics.

[70]  Andrew J. Wilson,et al.  Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer* , 2006, Journal of Biological Chemistry.

[71]  H. Comber,et al.  Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. , 2006, Cancer research.

[72]  G. Fantuzzi,et al.  Histone Hyperacetylation Is Associated with Amelioration of Experimental Colitis in Mice1 , 2006, The Journal of Immunology.

[73]  C. Horvath,et al.  Positive and Negative Regulation of the Innate Antiviral Response and Beta Interferon Gene Expression by Deacetylation , 2006, Molecular and Cellular Biology.

[74]  Bogdan Tanasa,et al.  Regulation of Th2 differentiation and Il4 locus accessibility. , 2006, Annual review of immunology.

[75]  M. V. Van Dyke,et al.  Tumour necrosis factor‐α depletes histone deacetylase 1 protein through IKK2 , 2006 .

[76]  George A. Calin,et al.  Mammalian microRNAs: a small world for fine-tuning gene expression , 2006, Mammalian Genome.

[77]  R. Stauber,et al.  Acetylation of Stat1 modulates NF-B activity , 2006 .

[78]  I. Adcock,et al.  Histone deacetylase 2–mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression , 2006, The Journal of experimental medicine.

[79]  E. Seto,et al.  Acetylation and deacetylation of non-histone proteins. , 2005, Gene.

[80]  M. T. Pedersen,et al.  Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. , 2005, Cancer research.

[81]  Hiroko Yamashita,et al.  Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast* , 2005, Breast Cancer Research and Treatment.

[82]  C. Bradbury,et al.  Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors , 2005, Leukemia.

[83]  P. Barnes.  Molecular mechanisms and cellular effects of glucocorticosteroids. , 2005, Immunology and allergy clinics of North America.

[84]  Xiuli Wang,et al.  Interleukin-12 p40 promoter activity is regulated by the reversible acetylation mediated by HDAC1 and p300. , 2005, Cytokine.

[85]  G. Stephanopoulos,et al.  Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis , 2005, Journal of Neuroimmunology.

[86]  M. Kaplan,et al.  Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells , 2005, The Journal of experimental medicine.

[87]  C. Hawrylowicz,et al.  Repression of Interleukin-5 Transcription by the Glucocorticoid Receptor Targets GATA3 Signaling and Involves Histone Deacetylase Recruitment* , 2005, Journal of Biological Chemistry.

[88]  K. Bhalla.  Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  K. Grønbæk,et al.  Microarray‐based classification of diffuse large B‐cell lymphoma , 2005, European journal of haematology.

[90]  I. Adcock,et al.  Decreased histone deacetylase activity in chronic obstructive pulmonary disease. , 2005, The New England journal of medicine.

[91]  L. Coussens,et al.  The interplay between innate and adaptive immunity regulates cancer development , 2005, Cancer Immunology, Immunotherapy.

[92]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[93]  Phillip D Zamore,et al.  Perspective: machines for RNAi. , 2005, Genes & development.

[94]  F. Blanchard,et al.  Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? , 2005, Drug discovery today.

[95]  G. Perez,et al.  Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[96]  Y. E. Chin,et al.  Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue , 2005, Science.

[97]  H. Kwon,et al.  Trichostatin A attenuates airway inflammation in mouse asthma model , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[98]  P. Marks,et al.  Apoptotic and autophagic cell death induced by histone deacetylase inhibitors , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[99]  Hiroko Yamashita,et al.  HDAC6 Expression Is Correlated with Better Survival in Breast Cancer , 2004, Clinical Cancer Research.

[100]  J. O’Shea,et al.  Discrete Roles for Histone Acetylation in Human T Helper 1 Cell-specific Gene Expression* , 2004, Journal of Biological Chemistry.

[101]  M. Cleary,et al.  Dimerization: a versatile switch for oncogenesis. , 2004, Blood.

[102]  L. Augenlicht,et al.  Requirement of Histone Deacetylase Activity for Signaling by STAT1* , 2004, Journal of Biological Chemistry.

[103]  J. R. Somoza,et al.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.

[104]  David E Levy,et al.  Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[105]  H. Ling,et al.  The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. , 2004, The Biochemical journal.

[106]  S. Hiebert,et al.  Role of RUNX family members in transcriptional repression and gene silencing , 2004, Oncogene.

[107]  Shiyong Li,et al.  Identification of interleukin‐8 as estrogen receptor‐regulated factor involved in breast cancer invasion and angiogenesis by protein arrays , 2004, International journal of cancer.

[108]  F. Sánchez‐Madrid,et al.  HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. , 2004, Immunity.

[109]  C. Dinarello,et al.  Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[110]  I. Adcock,et al.  Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase , 2004, The Lancet.

[111]  I. Adcock,et al.  Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. , 2004, Biochemical and biophysical research communications.

[112]  T. Aune,et al.  Long-range histone acetylation of the Ifng gene is an essential feature of T cell differentiation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[113]  T. Naoe,et al.  Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation , 2003, Oncogene.

[114]  K. Basso,et al.  Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6 , 2003, Leukemia & lymphoma.

[115]  K. Glaser,et al.  Role of class I and class II histone deacetylases in carcinoma cells using siRNA. , 2003, Biochemical and biophysical research communications.

[116]  P. J. van den Elsen,et al.  DNA methylation and expression of major histocompatibility complex class I and class II transactivator genes in human developmental tumor cells and in T cell malignancies. , 2003, Clinical immunology.

[117]  Jorge A. Almenara,et al.  The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. , 2003, Cancer research.

[118]  G. Morgan,et al.  Epigenetic consequences of AML1–ETO action at the human c‐FMS locus , 2003, The EMBO journal.

[119]  V. Kiermer,et al.  HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. , 2003, Immunity.

[120]  J. Ting,et al.  Histone Deacetylase 1/mSin3A Disrupts Gamma Interferon-Induced CIITA Function and Major Histocompatibility Complex Class II Enhanceosome Formation , 2003, Molecular and Cellular Biology.

[121]  E. Seto,et al.  Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. , 2003, Current opinion in genetics & development.

[122]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[123]  L. Nie,et al.  STAT5‐induced Id‐1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPβ , 2003, The EMBO journal.

[124]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[125]  A. Lucas,et al.  IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells , 2003, Oncogene.

[126]  W. Greene,et al.  Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF‐κB , 2002, The EMBO journal.

[127]  B. Schuettengruber,et al.  Activation of the Mouse Histone Deacetylase 1 Gene by Cooperative Histone Phosphorylation and Acetylation , 2002, Molecular and Cellular Biology.

[128]  R. Strieter.  Interleukin-8: a very important chemokine of the human airway epithelium. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[129]  R. Redner.  Variations on a theme: the alternate translocations in APL , 2002, Leukemia.

[130]  Minoru Yoshida,et al.  FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. , 2002, Cancer research.

[131]  M. Esteller.  CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future , 2002, Oncogene.

[132]  Fred Asselbergs,et al.  Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family* , 2002, The Journal of Biological Chemistry.

[133]  Christopher K. Glass,et al.  Exchange of N-CoR Corepressor and Tip60 Coactivator Complexes Links Gene Expression by NF-κB and β-Amyloid Precursor Protein , 2002, Cell.

[134]  Anjana Rao,et al.  TH cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes , 2002, Nature Immunology.

[135]  P. Pandolfi,et al.  The t(8;21) fusion protein, AML1–ETO, specifically represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia , 2002, Nature Medicine.

[136]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.

[137]  S. Ghosh,et al.  The Phosphorylation Status of Nuclear NF-ΚB Determines Its Association with CBP/p300 or HDAC-1 , 2002 .

[138]  J. Durbin,et al.  Cis elements for transporter associated with antigen-processing-2 transcription: two new promoters and an essential role of the IFN response factor binding element in IFN-gamma-mediated activation of the transcription initiator. , 2002, International immunology.

[139]  J. Schroeder,et al.  Histone deacetylation inhibits IL4 gene expression in T cells. , 2002, The Journal of allergy and clinical immunology.

[140]  C. Murre,et al.  The function of E- and id proteins in lymphocyte development , 2001, Nature Reviews Immunology.

[141]  F. Garrido,et al.  Rexpression of HLA class I antigens and restoration of antigen‐specific CTL response in melanoma cells following 5‐aza‐2′‐deoxycytidine treatment , 2001, International journal of cancer.

[142]  S. Tsuzuki,et al.  Histone deacetylase 3 associates with and represses the transcription factor GATA-2. , 2001, Blood.

[143]  Eric Verdin,et al.  Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation , 2001, Science.

[144]  R. Kiessling,et al.  Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. , 2001, Blood.

[145]  J. Cavaillon,et al.  Pro- versus anti-inflammatory cytokines: myth or reality. , 2001, Cellular and molecular biology.

[146]  J. Ihle.  The Stat family in cytokine signaling. , 2001, Current opinion in cell biology.

[147]  I. Adcock,et al.  Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[148]  G. Kammer,et al.  Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-γ gene and protein expression in lupus T cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[149]  T. Tomasi,et al.  Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors1 , 2000, The Journal of Immunology.

[150]  H. Saito,et al.  Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. , 2000, Blood.

[151]  I. Adcock,et al.  Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12 , 2000, Molecular and Cellular Biology.

[152]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[153]  C. Murre,et al.  Helix-Loop-Helix Proteins: Regulators of Transcription in Eucaryotic Organisms , 2000, Molecular and Cellular Biology.

[154]  D. Levy,et al.  Stat Protein Transactivation Domains Recruit p300/CBP through Widely Divergent Sequences* , 1999, The Journal of Biological Chemistry.

[155]  D. H. Zhang,et al.  Differential responsiveness of the IL-5 and IL-4 genes to transcription factor GATA-3. , 1998, Journal of immunology.

[156]  J. Bertoglio,et al.  Recent Advances in the Understanding of Interleukin-2 Signal Transduction , 1998, Journal of Clinical Immunology.

[157]  G. Klein,et al.  Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. , 1998, Journal of immunology.

[158]  S. Gullans,et al.  Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. , 1998, Biochemical and biophysical research communications.

[159]  P. Zeitlin,et al.  A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. , 1998, American journal of respiratory and critical care medicine.

[160]  R. Tampé,et al.  Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10 , 1997 .

[161]  K. Kuchler,et al.  Identification of mouse histone deacetylase 1 as a growth factor-inducible gene , 1997, Molecular and cellular biology.

[162]  S. Cohen,et al.  Cytokine function: a study in biologic diversity. , 1996, American journal of clinical pathology.

[163]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[164]  F. Chan,et al.  A role for the orphan steroid receptor Nur77 in apoptosis accompanying antigen-induced negative selection. , 1995, Immunity.

[165]  C. Meijer,et al.  Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. , 1994, British Journal of Cancer.

[166]  B. Calnan,et al.  Requirement for the orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas , 1994, Nature.

[167]  P. Stern,et al.  Evaluation of multiple biologic parameters in cervical carcinoma: high macrophage infiltration in HPV-associated tumors , 1992, International Journal of Gynecologic Cancer.

[168]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[169]  B. Aggarwal,et al.  Human interleukin 1 is a cytocidal factor for several tumor cell lines. , 1985, Journal of immunology.

[170]  A. Feinberg,et al.  Hypomethylation distinguishes genes of some human cancers from their normal counterparts , 1983, Nature.

[171]  P. Leder,et al.  Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis , 1975, Science.

[172]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[173]  P. Atadja,et al.  The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance , 2009, Nature Immunology.

[174]  T. Tomasi,et al.  Histone deacetylase regulation of immune gene expression in tumor cells , 2008, Immunologic research.

[175]  S. Emanuele,et al.  Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). , 2008, International journal of oncology.

[176]  F. Garrido,et al.  Role of altered expression of HLA class I molecules in cancer progression. , 2007, Advances in experimental medicine and biology.

[177]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[178]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[179]  U. Ritz,et al.  Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation , 2006, International journal of cancer.

[180]  David A Jones,et al.  Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. , 2004, Molecular pharmacology.

[181]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.